Hookipa Pharma (HOOK) Competitors $0.84 +0.06 (+7.71%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOOK vs. CNTB, RNTX, PEPG, RMTI, KPTI, HOWL, NRXP, KZR, RVPH, and LVTXShould you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Connect Biopharma (CNTB), Rein Therapeutics (RNTX), PepGen (PEPG), Rockwell Medical (RMTI), Karyopharm Therapeutics (KPTI), Werewolf Therapeutics (HOWL), NRx Pharmaceuticals (NRXP), Kezar Life Sciences (KZR), Reviva Pharmaceuticals (RVPH), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical preparations" industry. Hookipa Pharma vs. Connect Biopharma Rein Therapeutics PepGen Rockwell Medical Karyopharm Therapeutics Werewolf Therapeutics NRx Pharmaceuticals Kezar Life Sciences Reviva Pharmaceuticals LAVA Therapeutics Connect Biopharma (NASDAQ:CNTB) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Do institutionals & insiders believe in CNTB or HOOK? 58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 3.3% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to CNTB or HOOK? In the previous week, Connect Biopharma's average media sentiment score of 0.00 equaled Hookipa Pharma'saverage media sentiment score. Company Overall Sentiment Connect Biopharma Neutral Hookipa Pharma Neutral Which has better earnings and valuation, CNTB or HOOK? Connect Biopharma has higher earnings, but lower revenue than Hookipa Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConnect Biopharma$24.12M1.56-$59.50MN/AN/AHookipa Pharma$43.95M0.21-$81.58M-$3.52-0.22 Which has more volatility & risk, CNTB or HOOK? Connect Biopharma has a beta of -0.22, indicating that its stock price is 122% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Is CNTB or HOOK more profitable? Connect Biopharma has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Connect Biopharma's return on equity of 0.00% beat Hookipa Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Connect BiopharmaN/A N/A N/A Hookipa Pharma -86.74%-33.31%-21.65% Does the MarketBeat Community favor CNTB or HOOK? Hookipa Pharma received 72 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 73.08% of users gave Connect Biopharma an outperform vote while only 69.47% of users gave Hookipa Pharma an outperform vote. CompanyUnderperformOutperformConnect BiopharmaOutperform Votes1973.08% Underperform Votes726.92% Hookipa PharmaOutperform Votes9169.47% Underperform Votes4030.53% Do analysts rate CNTB or HOOK? Connect Biopharma currently has a consensus price target of $8.00, suggesting a potential upside of 1,076.47%. Hookipa Pharma has a consensus price target of $23.00, suggesting a potential upside of 2,848.72%. Given Hookipa Pharma's higher possible upside, analysts clearly believe Hookipa Pharma is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hookipa Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryConnect Biopharma beats Hookipa Pharma on 8 of the 13 factors compared between the two stocks. Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHookipa PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.41M$6.51B$5.35B$7.51BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-0.217.0021.9618.05Price / Sales0.21260.09391.99104.31Price / CashN/A65.6738.2034.62Price / Book0.096.346.744.14Net Income-$81.58M$142.49M$3.21B$247.59M7 Day Performance0.87%6.44%4.00%3.51%1 Month Performance-35.54%-9.07%-7.00%-5.80%1 Year Performance-90.82%-2.74%15.59%2.83% Hookipa Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHookipa Pharma2.212 of 5 stars$0.84+7.7%$23.00+2,637.8%-89.8%$10.13M$43.95M-0.2356CNTBConnect Biopharma2.7442 of 5 stars$0.65+4.1%$8.00+1,129.1%-51.1%$36.03M$24.12M0.00110Gap UpHigh Trading VolumeRNTXRein TherapeuticsN/A$1.66-2.9%N/AN/A$35.97MN/A-0.539News CoverageGap DownPEPGPepGen2.6587 of 5 stars$1.10-2.7%$10.33+839.4%-86.3%$35.96MN/A-0.3730News CoverageRMTIRockwell Medical3.8609 of 5 stars$1.05-1.4%$4.00+282.8%-24.8%$35.59M$101.49M-20.90300Positive NewsGap UpKPTIKaryopharm Therapeutics3.2096 of 5 stars$4.21-1.9%$57.50+1,265.8%-61.7%$35.44M$145.24M-4.13380News CoverageHigh Trading VolumeHOWLWerewolf Therapeutics2.5497 of 5 stars$0.77+8.7%$9.00+1,066.1%-86.7%$34.60M$1.89M-0.5040NRXPNRx Pharmaceuticals1.763 of 5 stars$2.03-1.0%$28.25+1,291.6%-35.1%$34.34MN/A-0.952KZRKezar Life Sciences3.0372 of 5 stars$4.32+9.4%$39.50+814.4%-44.6%$31.56M$7M-0.3360RVPHReviva Pharmaceuticals2.2464 of 5 stars$0.78+15.0%$10.00+1,188.5%-71.8%$31.54MN/A-0.705Analyst ForecastNews CoverageLVTXLAVA Therapeutics1.6236 of 5 stars$1.16+6.4%$3.17+173.0%-54.4%$30.51M$11.98M-1.1360Gap Down Related Companies and Tools Related Companies Connect Biopharma Competitors Rein Therapeutics Competitors PepGen Competitors Rockwell Medical Competitors Karyopharm Therapeutics Competitors Werewolf Therapeutics Competitors NRx Pharmaceuticals Competitors Kezar Life Sciences Competitors Reviva Pharmaceuticals Competitors LAVA Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOOK) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
